Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

DISEASE CHARACTERISTICS: One of the following diagnoses: Acute myeloid leukemia Accelerated/blastic phase of a myeloproliferative disorder (i.e., greater than 10% blasts in bone marrow or presence of extramedullary disease) Myelodysplastic syndrome Acute lymphocytic leukemia with expression of CD33 Greater than 20% blast population No evidence of CNS disease Relapsed after previously achieving complete remission Must have previously had peripheral blood stem cells or bone marrow cells harvested and cryopreserved while in remission Greater than 25% of bone marrow blasts must be CD33 positive PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: LVEF greater than 50% by ECG or MUGA No history of cardiomyopathy or symptomatic congestive heart failure Pulmonary: DLCO at least 50% predicted Other: Not pregnant or nursing Negative pregnancy test HIV negative No other concurrent active malignancy No known sensitivity to E. coli derived products PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified